| 29/07/26 | 07:00:01 | 29 Jul 2026 | | Half Yearly Report to 30 June 2026 |
| 14/07/26 | 10:02:13 | 14 Jul 2026 | | Sub-division |
| 09/06/26 | 07:00:05 | 9 Jun 2026 | | Publication of Phase 1 Clinical Trial |
| 05/06/26 | 07:00:03 | 5 Jun 2026 | | Commercialisation, Phase II Results & Revenue Path |
| 03/06/26 | 11:30:00 | 3 Jun 2026 | | Result of AGM |
| 03/06/26 | 07:00:01 | 3 Jun 2026 | | AGM Statement and Business Update |
| 13/05/26 | 07:00:06 | 13 May 2026 | | AMENDEMENT TO NOTICE OF ANNUAL GENERAL MEETING |
| 12/05/26 | 14:24:50 | 12 May 2026 | | NOTICE OF ANNUAL GENERAL MEETING |
| 08/05/26 | 07:00:01 | 8 May 2026 | | KIRKSTALL AWARDED BBSRC/NC3Rs GRANT: GLIOBLASTOMA |
| 30/04/26 | 16:18:46 | 30 Apr 2026 | | Annual Report for the Year Ended 31 December 2025 |
| 19/02/26 | 10:48:08 | 19 Feb 2026 | | Board Appointment |
| 11/02/26 | 07:00:08 | 11 Feb 2026 | | Update and IB Nimble Webinar – 27 February 2026 |
| 16/01/26 | 07:00:06 | 16 Jan 2026 | | IBAI: Strategic Direction Fueling Organic Growth |
| 10/12/25 | 09:43:39 | 10 Dec 2025 | | Expansion Global Distribution Agreement with GE |
| 26/11/25 | 14:50:50 | 26 Nov 2025 | | Release of Next-Generation IB Clinic |
| 24/11/25 | 09:56:17 | 24 Nov 2025 | | Board Changes |
| 13/11/25 | 11:24:05 | 13 Nov 2025 | | Fractional Tumor Burden Mapping Enhances GBM Trial |
| 10/11/25 | 15:14:48 | 10 Nov 2025 | | IB Announces Completion of Phase 1 Trial of GaM |
| 16/10/25 | 07:00:09 | 16 Oct 2025 | | Further Re: Purchase of interest in Kirkstall Ltd |
| 14/10/25 | 12:15:35 | 14 Oct 2025 | | Purchase of Kirkstall and CLN - Correction |
| 14/10/25 | 07:00:10 | 14 Oct 2025 | | Purchase of Kirkstall and CLN with Truetide plc |
| 03/10/25 | 12:16:47 | 3 Oct 2025 | | Vivan Therapeutics and IB Announce Partnership |
| 16/09/25 | 15:49:53 | 16 Sept 2025 | | IB Enters Agreement with MedImageMetric |
| 13/08/25 | 11:48:19 | 13 Aug 2025 | | Half-year Report |
| 07/08/25 | 11:22:41 | 7 Aug 2025 | | Grant of Share Options |
| 21/07/25 | 07:00:08 | 21 Jul 2025 | | IB Announces Soft Close to Phase 1 Trial |
| 09/07/25 | 17:14:35 | 9 Jul 2025 | | Director/PDMR Dealing |
| 12/06/25 | 10:30:35 | 12 Jun 2025 | | IB Provides Update on BTD Application |
| 27/05/25 | 07:00:15 | 27 May 2025 | | Change of Name |
| 22/05/25 | 14:23:17 | 22 May 2025 | | Result of AGM |
| 02/05/25 | 07:29:01 | 2 May 2025 | | Application: FDA Breakthrough Therapy Designation |
| 29/04/25 | 10:49:12 | 29 Apr 2025 | | Notice of AGM |
| 25/04/25 | 13:46:13 | 25 Apr 2025 | | Publication of Annual Report |
| 11/04/25 | 15:32:25 | 11 Apr 2025 | | Promising Preliminary Results of Phase 1 Study |
| 18/03/25 | 10:38:02 | 18 Mar 2025 | | Placing to raise £250,000 |
| 03/02/25 | 07:00:06 | 3 Feb 2025 | | IB Expands Distribution with Blackford |
| 22/01/25 | 07:00:05 | 22 Jan 2025 | | Operations Update |
| 10/01/25 | 07:49:29 | 10 Jan 2025 | | IB and Prism Secure First Installation |
| 20/11/24 | 07:00:02 | 20 Nov 2024 | | Imaging Biometrics Expands Distribution |
| 19/11/24 | 11:27:03 | 19 Nov 2024 | | Board Changes |
| 05/11/24 | 07:00:02 | 5 Nov 2024 | | New Patent Application and Trading Update |
| 15/10/24 | 10:28:36 | 15 Oct 2024 | | Holding(s) in Company |
| 15/10/24 | 07:00:09 | 15 Oct 2024 | | IQ-AI Issues Letter to Shareholders |
| 14/10/24 | 12:08:15 | 14 Oct 2024 | | Holding(s) in Company |
| 14/10/24 | 12:05:29 | 14 Oct 2024 | | PDMR dealing and TR1 announcement |
| 11/10/24 | 10:42:37 | 11 Oct 2024 | | Acquisition of Interest by Braveheart |
| 13/08/24 | 14:53:23 | 13 Aug 2024 | | Half-year Report |
| 25/06/24 | 09:59:49 | 25 Jun 2024 | | IB Opens Expanded Access Program |
| 14/06/24 | 08:38:49 | 14 Jun 2024 | | Clinical Trial Updates |
| 29/05/24 | 15:08:33 | 29 May 2024 | | Result of AGM |
